Too Soon To Say If US FDA Device Reforms Are Working, Says Independent Report
This article was originally published in SRA
The US Food and Drug Administration has adopted all of the recommendations that consulting firm Booz Allen Hamilton has made in the past two years to improve its medical device review process, but it is still too early to say if the changes have improved overall performance.
You may also be interested in...
Industry, US FDA Strike $1Bn Deal After Contentious User-Fee Negotiations
FDA and industry have finally struck a tentative deal that, with Congressional approval, aims to raise nearly a billion dollars over five years. It also holds FDA to higher quality metrics while starting a pilot project to use real-world evidence in tracking devices on the market.
Teva’s ‘Skinny Label’ Dispute Edges Toward Supreme Court With Government’s Backing
US Solicitor General urges the Supreme Court to grant Teva's petition, arguing that the Federal Circuit was wrong in ruling that Teva's carved-out labeling for generic carvedilol induced infringement of GlaxoSmithKine's brand product.
UK Updates Guidance To Reflect EU Medtech Extensions
The EU’s decision to extend the Medical Device Regulation transition periods for legacy medical device directives products will be mirrored in the UK, which also continues to evolve its post-Brexit medtech regulatory system.